论文部分内容阅读
一个国际工作组对1990年首次发表的急性髓系白血病(AML)诊断和疗效标准进行了修订,同时,为了更好地阐释数据和提高临床试验间的可比性,还对治疗结局和报告标准作出了界定。发表以来,使人们对临床相关的急性白血病的生物学和分子遗传学的了解加深了很多,理应将这些融入疗效标准。与1990年建议不同之处是包括了一种白血病无病状况及涵盖细胞遗传学和分子生物学缓解、缓解期在内的完全缓解新标准。保存活的原始细胞对有关疾病治疗的进步来说是重要的。
An international working group revised the criteria for the diagnosis and efficacy of acute myeloid leukemia (AML), first published in 1990, and also made recommendations on treatment outcomes and reporting criteria to better interpret the data and improve the comparability of clinical trials Defined. Since its publication, people’s understanding of the biology and molecular genetics of clinically relevant acute leukemia has deepened, and these should be incorporated into the standard of care. The difference from the 1990 recommendation is the inclusion of a new leukemia disease-free status and a new standard of complete remission covering cytogenetics and molecular biology, including remission. Preserving living blast cells is important for the progress of the treatment of the disease.